Institutions Along With Private Equity Firms Who Hold Considerable Shares InQ32 Bio Inc. (NASDAQ:QTTB) Come Under Pressure; Lose 17% of Holdings Value
Institutions Along With Private Equity Firms Who Hold Considerable Shares InQ32 Bio Inc. (NASDAQ:QTTB) Come Under Pressure; Lose 17% of Holdings Value
Key Insights
主要見解
- Significant control over Q32 Bio by private equity firms implies that the general public has more power to influence management and governance-related decisions
- 51% of the business is held by the top 4 shareholders
- 22% of Q32 Bio is held by Institutions
- 私募股權公司對Q32 Bio的顯著控制意味着公衆在管理和治理相關決策上有更大的影響力
- 前4大股東持有51%的業務股份
- 22%的Q32 Bio股份由機構持有
If you want to know who really controls Q32 Bio Inc. (NASDAQ:QTTB), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 51% to be precise, is private equity firms. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道誰真正控制Q32 Bio Inc.(納斯達克:QTTB),那麼你需要查看其股權登記的構成。持有該公司最多股份的群體,大約51%的股份,正是私募股權公司。也就是說,該集團在股票上漲時能夠獲得最大的收益(或在下跌時損失最大)。
While institutions who own 22% came under pressure after market cap dropped to US$532m last week,private equity firms took the most losses.
在擁有22%的機構在市值上週下降至53200萬美元后受到壓力時,股權投資公司損失最大。
Let's delve deeper into each type of owner of Q32 Bio, beginning with the chart below.
讓我們深入了解Q32 Bio的每種所有者類型,從下面的圖表開始。
What Does The Institutional Ownership Tell Us About Q32 Bio?
機構所有權告訴我們關於Q32 Bio什麼?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。
Q32 Bio already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Q32 Bio's historic earnings and revenue below, but keep in mind there's always more to the story.
Q32 Bio已經在股份登記上有機構。事實上,他們在公司中擁有相當可觀的股份。這意味着爲這些機構工作的分析師已經研究過這隻股票,並且他們喜歡它。但是和其他人一樣,他們也可能是錯的。當多個機構持有一隻股票時,總是存在他們處於"擁擠交易"的風險。當這樣的交易失敗時,多個參與方可能會競爭快速賣出股票。在沒有增長曆史的公司中,這種風險更高。您可以在下面看到Q32 Bio的歷史收益和營業收入,但請記住,故事總是有更多內容。
Hedge funds don't have many shares in Q32 Bio. The company's largest shareholder is OrbiMed Advisors LLC, with ownership of 18%. In comparison, the second and third largest shareholders hold about 17% and 9.1% of the stock.
對沖基金在Q32 Bio的股份並不多。該公司最大的股東是OrbiMed Advisors LLC,持有18%的股份。相比之下,第二和第三大股東分別持有約17%和9.1%的股票。
On looking further, we found that 51% of the shares are owned by the top 4 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.
進一步觀察後,我們發現前4大股東擁有51%的股份。換句話說,這些股東對公司決策具有重要影響力。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
儘管研究公司的機構持股可以增加您的研究價值,但研究分析師的建議也是一個好習慣,以更深入地了解股票的預期表現。有相當數量的分析師關注該股,因此了解他們對未來的總體觀點可能很有用。
Insider Ownership Of Q32 Bio
Q32 Bio的內部持股
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
雖然「內部人士」的明確定義具有主觀性,但幾乎所有人都認爲董事會成員是內部人士。公司管理業務,但首席執行官即使是董事會成員,也要向董事會負責。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。
Our data suggests that insiders own under 1% of Q32 Bio Inc. in their own names. It seems the board members have no more than US$3.3m worth of shares in the US$532m company. We generally like to see a board more invested. However it might be worth checking if those insiders have been buying.
我們的數據表明,內部人士在Q32 Bio Inc.的個人名下持有的股份不足1%。 看起來董事會成員在這家市值53200萬美元的公司中持有的股票價值不超過330萬美元。我們通常希望看到一個更投入的董事會。不過,值得檢查一下這些內部人士是否有在買入。
General Public Ownership
一般大衆所有權
The general public-- including retail investors -- own 20% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
一般公衆(包括散戶投資者)擁有公司的20%股份,因此不能輕易忽略。雖然這個群體不能必然佔據主導地位,但它肯定可以對公司的運營產生實際的影響。
Private Equity Ownership
股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。
Private equity firms hold a 51% stake in Q32 Bio. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
股權投資公司持有Q32 Bio的51%股份。這表明他們在關鍵政策決策中可能具有影響力。有些人可能喜歡這樣,因爲股權投資有時是積極份子,會對管理層負責。但有時,股權投資也在退出,因爲已經將公司上市。
Public Company Ownership
上市公司所有權
We can see that public companies hold 6.2% of the Q32 Bio shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.
我們可以看到,上市公司持有Q32 Bio發行的6.2%股份。這可能是出於戰略利益,兩家公司之間可能有相關的商業利益。他們可能已經分拆。這一持股狀態可能值得進一步調查。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 3 warning signs for Q32 Bio (2 are significant!) that you should be aware of before investing here.
雖然考慮擁有一家公司不同群體是非常重要的,但還有其他因素更爲重要。例如,我們發現Q32 Bio有3個警告信號(2個是顯著的!)你在這裏投資前應該了解這些風險。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。
譯文內容由第三人軟體翻譯。